Tyrosine News and Research

RSS

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths.

21 Feb 2011

Protein cross-linking enzymes in foods can affect physiological characteristics

Protein modification via enzymatic cross-linking is an attractive way for altering food structure so as to create products with increased quality and nutritional value. These modifications are expected to affect not only the structure and physico-chemical properties of proteins but also their physiological characteristics, such as digestibility in the GI-tract and allergenicity.

10 Feb 2011

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Three of the world's top lung associations have published a new international multidisciplinary classification of lung adenocarcinoma, the first revision to the classification in six years.

1 Feb 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Antibiotic may help in development of new anti-cancer agents: Researchers

An antibiotic known for its immunosuppressive functions could also point the way to the development of new anti-cancer agents, researchers at the Indiana University School of Medicine have reported.

28 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Researchers demystify death of brain cells in Parkinson's patients

Just 5 percent of Parkinson's disease cases can be explained by genetic mutation, while the rest have no known cause. But a new discovery by researchers at The University of Texas Health Science Center San Antonio may begin to explain why the vast majority of Parkinson's patients develop the progressive neurodegenerative disease.

10 Jan 2011

Symphogen closes €100 million stock to a group of investors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that it closed a €100 million placement of Preferred Stock to a group of investors.

6 Jan 2011

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Amoy Diagnostics announced today that its EGFR and BRAF mutation detection kits received market approval from China's State Food and Drug Administration (SFDA). The SFDA is the competent authority for regulating drugs and in vitro diagnostics in mainland China. The approval allows AmoyDx to market the EGFR and BRAF tests for clinical use in China.

15 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

Patients with chronic myeloid leukemia who were treated with nilotinib are found to be associated with better treatment adherence, less hospitalizations, and lower total health care costs than patients treated with dasatinib, according to a new study released by Analysis Group Inc., a leading provider of health care research and economic consulting.

8 Dec 2010

$Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH$

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

6 Dec 2010

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.

6 Dec 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

6 Dec 2010

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Pharmacyclics, Inc. today announced data from three Chronic Lymphocytic Leukemia presentations at the American Society of Hematology Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports clinical data from a pooled analysis of 54 patients with CLL or Small Lymphocytic Lymphoma treated with PCI-32765.

6 Dec 2010

Tyrosine News and Research

New study: Rapamycin reverses cardiac muscle damage in LEOPARD syndrome mouse model

Protein cross-linking enzymes in foods can affect physiological characteristics

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Antibiotic may help in development of new anti-cancer agents: Researchers

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Researchers demystify death of brain cells in Parkinson's patients

Symphogen closes €100 million stock to a group of investors

AmoyDx receives SFDA approval for its EGFR and BRAF mutations detection kits

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News